

Cushing's Syndrome Diagnostics and Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/CF5E24C4D1BCEN.html>

Date: November 2025

Pages: 135

Price: US\$ 4,850.00 (Single User License)

ID: CF5E24C4D1BCEN

Abstracts

The Global Cushing's Syndrome Diagnostics And Therapeutics Market was valued at USD 386.5 million in 2024 and is estimated to grow at a CAGR of 9.2% to reach USD 936.2 million by 2034.

The market is growing owing to the rising disease prevalence, expanding regulatory incentives, and increased investment in next-generation cortisol-modulating research, which strengthens adoption. The newer diagnostic approaches are improving accuracy in detecting hypercortisolemia, helping to minimize misdiagnosis and enhance long-term patient outcomes. The modern endocrine care is shifting toward precision-driven management, offering clinicians better tools for evaluating disease severity and determining effective treatment plans. The innovations aimed at correcting hormonal imbalance are transforming care for individuals who require safer, more sustainable therapeutic options. Traditional interventions often pose challenges for patients with recurring or difficult-to-treat conditions, which is driving interest in updated medical alternatives that offer more predictable and tolerable long-term outcomes.

The therapeutics category segment held 78.8% share in 2024 as medical management remains essential for individuals who cannot undergo surgical procedures or who face disease recurrence. The dominance of this segment is reinforced by broader access to targeted drug classes that improve overall treatment consistency and chronic care outcomes. These medicines provide mechanisms designed to regulate cortisol activity and allow clinicians to manage symptoms over extended periods with fewer complications.

The endogenous Cushing's syndrome segment generated USD 87 million in 2024 and

is projected to grow at an 8.6% CAGR through 2034. The growth in this area is supported by heightened clinical awareness, advancements in testing, and better differentiation of underlying disease origins. The development of specialty treatments and supportive regulatory designations is enabling wider access for individuals with complex endocrine disorders.

United States Cushing's Syndrome Diagnostics and Therapeutics Market was valued at USD 153.7 million in 2024. The regulatory systems, supportive reimbursement pathways, and a strong base of pharmaceutical innovators, including Novartis, Corcept Therapeutics, Pfizer, Recordati, Teva, Thermo Fisher Scientific, and other industry contributors, strengthen market performance. Rising rates of endocrine-related disorders and conditions, such as obesity and diabetes, continue to broaden the national patient population.

Key companies active in the Global Cushing's Syndrome Diagnostics and Therapeutics Market include Labcorp, Esteve, Salimetrics, ALPCO, Lucichem Pharma, DiaMetra, and other established industry participants. Leading companies in the Cushing's syndrome diagnostics and therapeutics field are expanding their presence by prioritizing continuous research investment, pursuing regulatory incentives, and forming strategic collaborations with clinical research organizations and academic partners. Firms are enhancing product portfolios through focused development of selective cortisol-modulating therapies and by improving diagnostic accuracy through advanced assay technologies. Companies are strengthening market access by optimizing commercialization strategies, securing favorable reimbursement, and expanding patient-support programs to encourage long-term therapy adherence.

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definition
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Data mining sources
 - 1.3.1 Global
 - 1.3.2 Regional/Country
- 1.4 Base estimates and calculations
 - 1.4.1 Base year calculation
 - 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis
- 2.2 Key market trends
 - 2.2.1 Regional trends
 - 2.2.2 Category trends
 - 2.2.3 Disease type trends
 - 2.2.4 End Use trends
- 2.3 CXO perspectives: Strategic imperatives
 - 2.3.1 Key decision points for industry executives
 - 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Rising prevalence of Cushing's syndrome
 - 3.2.1.2 Expansion of orphan drug designations and regulatory incentives

- 3.2.1.3 Advancements in diagnostic technologies
- 3.2.1.4 Increasing R&D investments in selective cortisol modulators
- 3.2.2 Industry pitfalls & challenges
 - 3.2.2.1 High treatment costs
 - 3.2.2.2 Diagnostic complexity and delayed detection
- 3.2.3 Market opportunities
 - 3.2.3.1 Increasing adoption of personalized medicine
- 3.3 Growth potential analysis
- 3.4 Investment landscape
- 3.5 Pipeline analysis
- 3.6 Future market trends
- 3.7 Reimbursement scenario
- 3.8 Regulatory landscape
- 3.9 Technology landscape
 - 3.9.1 Current technologies
 - 3.9.2 Emerging technologies
- 3.10 Gap analysis
- 3.11 Porter's analysis
- 3.12 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
 - 4.3.1 Global
 - 4.3.2 North America
 - 4.3.3 Europe
 - 4.3.4 Asia Pacific
 - 4.3.5 LAMEA
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
 - 4.6.1 Mergers & acquisitions
 - 4.6.2 Partnerships & collaborations
 - 4.6.3 Expansion plans

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY CATEGORY, 2021 - 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Therapeutics
 - 5.2.1 Surgery
 - 5.2.1.1 Transsphenoidal surgery
 - 5.2.1.2 Adrenalectomy
 - 5.2.2 Drugs
 - 5.2.2.1 Pituitary-directed drugs
 - 5.2.2.2 Adrenal steroidogenesis inhibitors
 - 5.2.2.3 Glucocorticoid receptor antagonists
 - 5.2.2.4 Other drugs
 - 5.2.3 Radiation Therapy
- 5.3 Diagnostics
 - 5.3.1 Inferior petrosal sinus sampling
 - 5.3.2 Late-night salivary cortisol test
 - 5.3.3 24-hour urine & blood cortisol panels
 - 5.3.4 Imaging tests
 - 5.3.5 Other diagnostic tests

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DISEASE TYPE, 2021 - 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Exogenous Cushing's syndrome
- 6.3 Endogenous Cushing's syndrome

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 - 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Hospitals & clinics
- 7.3 Homecare settings
- 7.4 Diagnostic centers
- 7.5 Other End Use

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 - 2034 (\$ MN)

- 8.1 Key trends

8.2 North America

8.2.1 U.S.

8.2.2 Canada

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 France

8.3.4 Spain

8.3.5 Italy

8.3.6 Netherlands

8.4 Asia Pacific

8.4.1 China

8.4.2 Japan

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.5 Latin America

8.5.1 Brazil

8.5.2 Mexico

8.5.3 Argentina

8.6 Middle East and Africa

8.6.1 South Africa

8.6.2 Saudi Arabia

8.6.3 UAE

CHAPTER 9 COMPANY PROFILES

9.1 ALPCO

9.2 Corcept THERAPEUTICS

9.3 DiaMetra

9.4 ESTEVE

9.5 labcorp

9.6 Lucichem Pharma

9.7 NOVARTIS

9.8 Pfizer

9.9 RECORDATI

9.10 SALIMETRICS

9.11 teva

9.12 Thermo Fisher SCIENTIFIC

I would like to order

Product name: Cushing's Syndrome Diagnostics and Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/CF5E24C4D1BCEN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF5E24C4D1BCEN.html>